SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Half Year Trading Update

16 Oct 2024 07:00

RNS Number : 3121I
Oxford Instruments PLC
16 October 2024
 

 

Oxford Instruments plc

Half-year trading update - 16 October 2024

 

 

Robust demand and order intake growthFull year trading in line with constant currency expectations

 

Oxford Instruments plc, a global provider of high technology products and services to many of the world's leading companies and scientific research communities, is today issuing a trading update for the half year ended 30 September 2024.

 

At constant currency, we expect to deliver circa 10% revenue growth for the first half, supported by order intake circa 3% ahead of the prior year. Adjusted operating profit will be slightly above last year. Group margin will be lower than last year, as expected, reflecting the mix effect of stronger revenue growth from Advanced Technologies.

 

On a reported basis, the currency headwind will result in adjusted operating profit and margin below the comparable period last year.

 

Imaging & Analysis

We have continued to see good growth in the first half of this financial year, with strong demand across our materials analysis and semiconductor markets. This more than offset softer demand from our healthcare & life science market. The division recorded a positive book-to-bill in the half year.

 

Advanced Technologies

Our compound semiconductor business continues to perform well, with strong revenue growth in the first half. In the quantum market, we have begun deliveries of an ongoing series of orders to a key customer, supporting good progress towards a return to profitability. The division continues to have good order book visibility.

 

Outlook

We expect to deliver our normal stronger second half trading performance. This will be supported by the execution of some larger orders in Advanced Technologies, as well as progress in our operational transformation and business restructuring projects, delivering efficiency and cost improvements in the second half of the year. We expect performance for the full year to be in line with expectations on a constant currency basis.

 

Based on prevailing exchange rates, the appreciation of sterling is expected to increase the currency headwind on operating profit for the full year by circa £1.5-2.0m from previous guidance.2

 

Oxford Instruments' results for the half year ending 30 September 2024 will be released on 12 November 2024.

 

 

Notes:

 

1. Adjusted operating profit is before amortisation and impairment of acquired intangible assets, acquisition items, restructuring costs and the mark-to-market revaluation of financial derivatives.

2. Guidance in our 2024 preliminary full-year results announcement in June pointed to a headwind of £8.4m to revenue and £6.2m to profit for the full year.

 

 

Enquiries:

 

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Gavin Hill, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations

 

Tel: 01865 393200

investors@oxinst.com

 

MHP Group

Katie Hunt/Tim Rowntree/Eleni Menikou/Veronica Farah

 

Tel: 07710 117517

oxfordinstruments@mhpgroup.com

 

- Ends -

Issued for and on behalf of Oxford Instruments plc

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductor, and healthcare & life science.

Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow.

Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress.

Founded in 1959 as the first technology business to be spun out fromOxfordUniversity, Oxford Instruments is now a global company listed on the FTSE250 index of the London Stock Exchange (OXIG).

For more information, visit www.oxinst.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKPBQABDDPKD
Date   Source Headline
12th Mar 202011:11 amPRNDirector/PDMR Shareholding
4th Mar 202010:02 amPRNAppointment of External Auditor
2nd Mar 202012:06 pmPRNTotal Voting Rights
2nd Mar 202012:02 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20207:00 amRNSDisposal of OI Healthcare business in the US
10th Feb 20201:49 pmPRNDirector/PDMR Shareholding
3rd Feb 202012:41 pmPRNTotal Voting Rights
29th Jan 20207:00 amRNSSale of Minority Share in Scienta Omicron
23rd Jan 202010:52 amPRNAdditional Listing
13th Jan 20209:55 amPRNDirector/PDMR Shareholding
10th Jan 202012:02 pmRNSPrice Monitoring Extension
9th Jan 202010:42 amPRNTotal Voting Rights
9th Jan 20209:41 amPRNBlocklisting - Interim Review
3rd Jan 20208:36 amPRNHolding(s) in Company
11th Dec 20194:03 pmPRNDirector/PDMR Shareholding
2nd Dec 20192:54 pmPRNTotal Voting Rights
12th Nov 201912:49 pmPRNDirector/PDMR Shareholding
12th Nov 20197:00 amRNSHalf-year Report
11th Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20194:34 pmPRNDirector/PDMR Shareholding
3rd Oct 201911:00 amPRNTotal Voting Rights
11th Sep 20193:30 pmPRNDirector/PDMR Shareholding
11th Sep 201912:12 pmPRNResult of AGM
11th Sep 201910:50 amPRNDirector/PDMR Shareholding
10th Sep 20197:00 amRNSChairman's AGM Statement 2019
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 20191:24 pmPRNHolding(s) in Company
13th Aug 201910:26 amPRNDirector/PDMR Shareholding
15th Jul 20194:26 pmPRNDirector/PDMR Shareholding
11th Jul 201911:49 amPRNDirector/PDMR Shareholding
1st Jul 201911:07 amPRNBlocklisting - Interim Review
27th Jun 20195:01 pmPRNHolding(s) in Company
26th Jun 20195:30 pmRNSRPC Group
11th Jun 20191:02 pmPRNDirector/PDMR Shareholding
11th Jun 20197:00 amRNSFinal Results
30th May 20191:18 pmPRNHolding(s) in Company
13th May 201910:27 amPRNDirector/PDMR Shareholding
11th Apr 201912:00 pmPRNDirector/PDMR Shareholding
11th Apr 20197:00 amRNSTrading Statement
22nd Mar 20197:00 amRNSContract win
11th Mar 20191:40 pmPRNDirector/PDMR Shareholding
12th Feb 20191:32 pmPRNDirector/PDMR Shareholding
1st Feb 20199:56 amPRNDirector Declaration
15th Jan 201910:28 amPRNAdditional Listing
14th Jan 20194:01 pmPRNBlocklisting - Interim Review
11th Jan 201910:28 amPRNDirector/PDMR Shareholding
3rd Jan 201912:26 pmPRNDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.